Funding & VC

Sofinnova Closes $815M Crossover II Fund for Late-Stage Life Sciences

Sofinnova Partners closed its Crossover II fund at €725M ($815M) to back some 15 clinical-stage European biotech and medtech firms through commercialization.

By Grace Kim

3 min read

Sofinnova Partners: $815 Million Crossover II Fund Closes To Back Late-Stage Life Sciences Companies
Sofinnova Partners: $815 Million Crossover II Fund Closes To Back Late-Stage Life Sciences CompaniesKost9n4 / pixabay

What's News

  • Sofinnova Partners closed Sofinnova Crossover II at €725 million (~$815 million), exceeding its target.
  • The fund will back roughly 15 clinical-stage biotech and medtech companies, primarily in Europe.
  • Crossover I exits included LimFlow (Inari Medical), Calliditas (Asahi Kasei), Amolyt Pharma (AstraZeneca) and Abivax's Nasdaq listing.
  • Crossover II has already invested in Hemab Therapeutics, CellCentric and Neurent Medical.
  • Founded in 1972, Sofinnova has invested in 500+ companies and manages over €4 billion in assets.

Sofinnova Partners has closed Sofinnova Crossover II at €725 million — roughly $815 million — beating its original fundraising target to become one of the largest vehicles dedicated to late-stage European life sciences companies.

The Paris-based venture firm plans to deploy the capital across approximately 15 companies over the fund's investment period. The primary focus is European clinical-stage biotechnology and medical technology firms preparing for later-stage development, global expansion, and commercialization. The fund will also pursue selected opportunities in the United States and other international markets.

Sofinnova reads the oversubscribed close as a signal. The firm said the fundraising reflects increasing investor confidence in European life sciences businesses building technologies with global commercial potential — companies that now need large pools of growth capital as they approach critical stages of clinical development.

What does the money actually fund?

Late-stage life sciences is expensive. Companies need substantial financing to push experimental therapies and devices through clinical testing, regulatory approval, and commercialization — the phases where capital requirements jump.

Crossover II is built for exactly that stretch. Its investment strategy targets companies with three attributes: promising scientific foundations, existing clinical validation, and leadership teams capable of scaling internationally.

Sofinnova argues the European market is now producing a rising number of competitive healthcare companies that lack access to substantial growth capital. The firm pairs its financing with industry expertise and strategic support rather than writing passive checks.

Does the first fund's track record justify the size?

Sofinnova's first crossover fund backs the pitch with exits. Its portfolio produced:

  • LimFlow, acquired by Inari Medical
  • Calliditas Therapeutics, acquired by Asahi Kasei
  • Amolyt Pharma, acquired by AstraZeneca
  • Abivax, which completed a Nasdaq listing

Crossover II has already put money to work. The fund has invested in Hemab Therapeutics, CellCentric, and Neurent Medical, and will keep hunting among biotech and medtech companies with differentiated products and clinical development programs.

Who is running the strategy — and who is backing it?

Five Sofinnova partners lead the Crossover II strategy: Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat, and David Evans. The European Tech Champions Initiative, a fund-of-funds managed by the European Investment Fund, anchors the vehicle with institutional support.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, framed the close in market terms: "The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialization."

Kinam Hong, partner at Sofinnova Partners, pointed to the pipeline quality: "We continue to see exceptional opportunities emerging across European life sciences. Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage. With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund."

The firm behind the fund is no newcomer. Sofinnova Partners was founded in 1972 and operates from Paris, London, and Milan. It has invested in more than 500 companies and manages more than €4 billion in assets, spanning life sciences and sustainability from early-stage formation through later-stage development.

The €725 million close deepens Sofinnova's capacity to keep European life sciences companies competitive on a global stage — and sets a benchmark for how much capital Europe's maturing biotech scene can now attract.

Source: pulse2.com

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,174 articles

Related articles

« Previous articleNext article »